Table 1 Baseline characteristics of the 1 L ARROW trial participants given pralsetinib and 1 L CGDB cohort given the best available therapy without adjustment.
Baseline characteristics | Best available therapy | Pralsetinib | SMD |
|---|---|---|---|
Sample size – n | 10 | 116 | – |
Age ≥ 65 – n (%) | 5 (50.0) | 49 (42.2) | 0.156 |
Male – n (%) | 2 (20.0) | 55 (47.4) | 0.606 |
Stage IV – n (%) | 7 (70.0) | 95 (81.9) | 0.281 |
Smoking status – n (%) | |||
History of smoking | 4 (40.0) | 45(38.8) | 0.23 |
No history of smoking | 6 (60.0) | 68(58.6) | |
Unknown | 0 (0.0) | 3 (2.6) | |
ECOG – n (%) | |||
0 | 5 (50.0) | 35 (30.2) | 1.017 |
1 | 3 (30.0) | 80 (69.0) | |
2 | 0 (0.0) | 1 (0.9) | |
Missing | 2 (20.0) | 0 (0.0) | |
Non-squamous histology – n (%) | 10 (100.0) | 115 (99.3) | 0.132 |
Time since diagnosis – median (IQR) | 1.50 (0.77, 8.77) | 1.76 (1.25, 2.51) | 0.069 |
Metastases: Brain/CNS site – n (%) | 1 (10.0) | 31 (26.7) | 0.442 |
Race – n (%) | |||
Other | 2 (20.0) | 53 (45.7) | 0.664 |
Unknown | 2 (20.0) | 6 (5.2) | |
White | 6 (60.0) | 57 (49.1) | |
